Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer

Cell & Bioscience
Dietmar ZechnerBrigitte Vollmar

Abstract

Preclinical evaluations of chemotherapies depend on clinically relevant animal models for pancreatic cancer. The injection of syngeneic murine adenocarcinoma cells is one efficient option to generate carcinomas in mice with an intact immune system. However, this option is constrained by the paucity of appropriate cell lines. The murine pancreatic adenocarcinoma cell lines 6606PDA and 7265PDA were compared to the 6606l cell line isolated from a liver metastasis from mice suffering from pancreatic cancer. In tissue culture 6606PDA and 6606l proliferated faster than 7265PDA. 7265PDA cells were, however, significantly more sensitive to gemcitabine as assessed by BrdU-incorporation and trypan blue exclusion assays in vitro. Within 1 week after injection of either one of these three cell lines into the pancreas of C57BL/6J mice, carcinomas were observed by T2 weighted magnetic resonance imaging and histology. Three weeks after injecting 6606PDA or 6606l cells large carcinomas could be characterized, which were surrounded by extensive desmoplastic reaction. After injection of 7265PDA cells, however, remission of cancer was observed between the first and the third week. Compared to 6606PDA cell derived carcinomas a higher apparent diff...Continue Reading

References

Jan 7, 2004·Cancer Cell·Sunil R HingoraniDavid A Tuveson
Feb 27, 2007·The American Journal of Pathology·James E TalmadgeAvraham Raz
Mar 15, 2008·Cancer Research·Chitta Ranjan PatraDebabrata Mukhopadhyay
Jun 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William W TsengEdgar G Engleman
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jul 2, 2011·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·L I ParteckeA Stier
Feb 27, 2013·The American Journal of Pathology·Alexej BobrowskiDietmar Zechner
Oct 1, 2008·Expert Opinion on Drug Discovery·Matthias Kapischke, Alexandra Pries
Mar 27, 2013·Nature Reviews. Gastroenterology & Hepatology·Raghuwansh P SahSuresh T Chari
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 18, 2015·BMC Cancer·Dietmar ZechnerBrigitte Vollmar

❮ Previous
Next ❯

Citations

Feb 9, 2017·Pharmacology & Therapeutics·Diana BehrensIduna Fichtner
Jan 19, 2019·Expert Opinion on Drug Discovery·Savita Bisht, Georg Feldmann
Apr 17, 2019·Acta Diabetologica·Valentina PasqualeLorenzo Piemonti
Apr 26, 2021·Advanced Drug Delivery Reviews·Marcel A HeinrichJai Prakash

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

ImageJ
Slicer3D

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.